CCHP Unveils Telehealth Reimbursement Guide for Providers

mHealthIntelligence | February 04, 2020

The Center for Connected Health Policy has unveiled a telehealth billing guide, aimed at helping healthcare providers navigate the confusing waters of connected health reimbursement. With roughly three-quarters of the nation’s hospitals and health systems now using telemedicine or mHealth technology, “it is not surprising then that the question of billing is the foremost question heard by telehealth resource centers, followed by ‘will I get paid?’” CCHP officials point out in their 21-page resource guide. And because reimbursement isn’t guaranteed for any specific service, it’s on the provider to navigate a path to payment. Telehealth reimbursement consistently ranks as one the largest barriers to adoption, thanks in part to restrictions placed on Medicare coverage by the Centers for Medicare & Medicaid Services, different protocols for Medicaid coverage in each state and varying policies among private payers. The CCHP guide focuses primarily on fee-for-service Medicare rules and Medicaid policies, as seen in California’s Medi-Cal program.

Spotlight

This short NHS RightCare video covers the Cancer focus pack and is designed to help healthcare economies work through the Commissioning for Value focus packs published in May 2016. It highlights key points and explains what the data is showing. The focus pack presents analysis of a wide range of indicators focussing on spend, activity, quality and outcomes. The focus pack presents analysis of a wide range of indicators focussing on spend, activity, quality and outcomes. The indicators have been chosen with advice from key stakeholders including the National Cancer Intelligence Network.

Spotlight

This short NHS RightCare video covers the Cancer focus pack and is designed to help healthcare economies work through the Commissioning for Value focus packs published in May 2016. It highlights key points and explains what the data is showing. The focus pack presents analysis of a wide range of indicators focussing on spend, activity, quality and outcomes. The focus pack presents analysis of a wide range of indicators focussing on spend, activity, quality and outcomes. The indicators have been chosen with advice from key stakeholders including the National Cancer Intelligence Network.

Related News

HEALTH TECHNOLOGY

Sense and TECOmedical Sign Distribution Agreement for Germany, Austria, Switzerland

Sense Biodetection | September 02, 2022

Global molecular diagnostics innovator, Sense Biodetection announced it has entered into a strategic agreement with TECOmedical for the non-exclusive distribution of Sense’s Veros COVID-19, the first test on the rapid, instrument-free, point-of-care Veros molecular testing platform. The self-contained, single-use Veros COVID-19 product produces PCR-quality results in about 15 minutes, unconstrained by a reader or need for external power. TECOmedical, a Eurobio Scientific Company, is a leading specialty medical distributor with proven success developing new markets with innovative technology. Effective immediately in Germany and Austria, and pending regulatory approval in Switzerland, the agreement is the latest in Sense’s planned EU distribution partnerships as it commercializes its Veros platform. “We are delighted to partner with TECOmedical to bring Veros COVID-19 to the market, building on the impressive reputation that TECOmedical has established with their customers,” stated Ryan Roberts, Chief Commercial Officer of Sense. “We’re optimistic that by adding the instrument-free Veros COVID-19 to their diagnostic portfolio, TECOmedical’s customers will be able to take advantage of a laboratory-quality molecular test that can enable improved access and faster diagnosis, helping them to provide exceptional care for their patients right at the point of use.” “We are always looking for innovative technologies that address an unmet need. Being able to offer an instrument free, PCR-quality result in minutes right at the Point of Care reflects our commitment to customers to bring solutions that help them overcome limitations of existing technologies and improve care. We are excited to launch Veros COVID-19 now and are eagerly anticipating an expanded Veros test menu in the future.” Marieluise Wippermann, CEO of TECOmedical Veros is the first and only instrument-free, single-use, rapid, point-of-care molecular diagnostic testing platform that produces lab-quality results in about 15 minutes. Using a proprietary, rapid molecular amplification technology, Veros aims to help to improve access to rapid, highly accurate, point of care testing for many more people, and help reduce the spread of COVID-19 with faster, more precise diagnoses. Veros COVID-19’s clinical performance was established in one of the most comprehensive clinical trials in COVID-19 diagnostic testing conducted to date. The multicentre study prospectively enrolled nearly 300 evaluable subjects during both the Delta and Omicron variant surges of the pandemic. All study sites represented near-patient testing / point-of-care environments, with all test operators reporting no prior formal laboratory training or experience. 100% of operators agreed the Veros COVID-19 was easy-to-use, read and understand the results, with minimal hands-on time required from start to finish. As the virus continues to evolve, Veros COVID-19 has maintained 100% conservation in all Variants of Interest and Concern identified to date by WHO and the US CDC, including all Omicron sub-variants. About Sense Biodetection Sense Biodetection is a global molecular diagnostics company focused on empowering patients and transforming healthcare access and affordability by bringing lab-quality results through easy-to-use, rapid, disposable molecular tests without the constraints of an instrument. The company's Veros product platform will enable widespread testing to enhance patient access, improve patient health and lower systemic healthcare costs. Backed by respected investors, such as Koch Disruptive Technologies, Cambridge Innovation Capital, Earlybird Health and Mercia Asset Management, Sense has launched its first product, Veros COVID-19, and is growing rapidly while building a portfolio of tests for other diseases. About TECOmedical The Swiss-based TECOmedical Group, a Eurobio Scientific company, with subsidiaries in Germany and Austria is a leading provider of in-vitro specialty test systems in medical diagnostic, based on Immunosorbent, Immunofluorescence and Molecular methodologies.

Read More

HEALTH TECHNOLOGY

Medtronic announces partnership with BioIntelliSense for exclusive U.S. distribution of multi-parameter wearable

Medtronic plc | September 01, 2022

Medtronic plc a global leader in healthcare technology, announced it has entered into a strategic partnership with BioIntelliSense, a continuous health monitoring and clinical intelligence company, for the exclusive U.S. hospital and 30-day post-acute hospital to home distribution rights of the BioButton® multi-parameter wearable for continuous, connected monitoring. The partnership enables the Medtronic Patient Monitoring business to offer access to a medical grade device that provides continuous vital sign measurements of general care patients in-hospital as well as post-discharge. This supports the simplification of care delivery through workflow automation, enabling proactive clinical intervention, and helping to address the implications of staffing shortages. Terms of the deal were not disclosed. The BioButton medical grade device, measuring up to 1,440 vital sign measurements per day, including skin temperature, respiratory rate at rest, and heart rate at rest, is the exclusive multi-parameter wearable for the Patient Monitoring business. This device, combined with advanced analytics, has the potential to help enable clinicians to better detect early signs of patient deterioration or, conversely, identify stable patients who may be candidates for earlier hospital discharge. The rechargeable BioButton device also has configurable acute and post-acute modes to continuously monitor patients as they transition from higher to lower acuity settings. "Our vision is to empower clinicians and patients with actionable insights to personalize care — anytime, anywhere," said Frank Chan, Ph.D., president of the Patient Monitoring business, which is part of the Medical Surgical Portfolio at Medtronic. "Today, our solutions touch more than 100 million patients annually in hospitals. Through our collaboration with BioIntelliSense, we will support continuous, connected care from in-hospital to home and expand our reach to help more patients in more places than ever before." With staffing shortages projected to reach 3.2 million healthcare workers by 20261, the Patient Monitoring business intends to continue to expand its HealthCast™ portfolio to improve workflow automation so clinicians can focus on what matters most — their patients. The HealthCast™ connectivity gateway helps increase workflow efficiency by connecting unconnected devices to the electronic medical records (EMR) and saves valuable staff time by reducing the burden of manual charting. The HealthCast™ VitalSync™ remote patient monitoring system enables clinicians to receive near real-time trend and alert data on web-enabled devices so they can act on patient deterioration earlier. With the addition of the BioButton multi-parameter wearable to the HealthCast portfolio, Medtronic can help even more general care patients inside and outside of the hospital, furthering our commitment to patient safety. "In partnership with Medtronic, we are poised to accelerate continuous connected care models that offer a new level of clinical surveillance and workflow efficiencies for hospitals that are challenged in today's environment of growing workforce shortages and cost of care management. This advanced remote physiologic monitoring simplifies care delivery to facilitate personalized patient care, clinical workflow automation and proactive clinical interventions." James Mault, M.D., founder and CEO of BioIntelliSense About BioIntelliSense BioIntelliSense is ushering in a new era of continuous health monitoring and clinical intelligence for Remote Patient Monitoring. Its medical-grade Data-as-a-Service (DaaS) platform seamlessly captures multi-parameter vital signs and physiological biometrics through an effortless patient experience. The medical grade BioButton® devices make remote monitoring and early detection simple. Through the platform's advanced analytics, clinicians have access to high-resolution patient trending and alerting to enable medical grade remote care from in-hospital to home. About the Patient Monitoring business at Medtronic The Patient Monitoring business is committed to transforming the future of health monitoring. Our vision is to empower clinicians and patients with actionable insights to personalize care. Our technologies, including HealthCast™ intelligent patient manager, VitalSync™ remote patient monitoring, Nellcor™ pulse oximetry, Microstream™ capnography, BIS™ brain monitoring, and INVOS™ regional oximetry are always on watch, helping clinicians keep patients safe. About Medtronic Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary.

Read More

HEALTH TECHNOLOGY

athenahealth Implements DrFirst’s Digital Engagement Solution to Encourage Patients to Follow Prescribed Treatment Plans

athenahealth, Inc. | August 03, 2022

athenahealth, a leading provider of network-enabled software and services for medical groups and healthcare organizations nationwide, and health technology pioneer, DrFirst, today announced they are partnering to help improve medication adherence and patient outcomes. athenahealth’s large user base will now be able to send patient medication notifications powered by DrFirst’s RxInform to reduce prescription abandonment and help patients adhere to their recommended medication therapies. Patients abandon 20% to 30% of new prescriptions, whether due to high out-of-pocket costs, concerns about side effects, procrastination, or other factors. This lack of medication adherence can lead to increased total cost of patient care and undesirable health outcomes, such as disease progression, hospitalization, or even death. Now, the athenahealth electronic health record system that helps providers maximize clinical productivity and focus on delivering high-quality care to patients connects with RxInform, which automatically triggers a secure message to a patient’s mobile device when a clinician sends a prescription order to a pharmacy. From the message, patients may receive cost savings opportunities as available for a prescribed therapy and can view detailed information regarding their prescriptions, with a focus on behavioral and educational issues that have been proven to reduce prescription abandonment. The experience is seamless for the prescriber and helps them ensure the best outcomes for their patients. “We are always looking for innovative ways to drive better results for our customers and their patients – especially as the industry shifts more toward value-based care. Every provider wants to minimize prescription abandonment rates because non-adherence to medication regimens negatively affects desired clinical outcomes. By adding RxInform to the latest release of athenaOne, we are immediately giving all our providers an automated function within their established prescribing workflows to support better patient outcomes.” Paul Brient, chief product officer for athenahealth Since 2017, RxInform has received more than three million patient ratings, with 92% overall positive scores. These results indicate that patients welcome these messages, presenting new opportunities for providers to nurture patient relationships and build loyalty outside of the exam room. “Primary care providers and specialists who care for high-risk patients need tools to help people take their medications as prescribed,” said G. Cameron Deemer, president of DrFirst. “We’re pleased to partner with athenahealth to give its network of approximately 145,000 providers access to the RxInform platform so they can help patients overcome the common hurdles that lead them to abandon their medications at the pharmacy.” About athenahealth, Inc. athenahealth creates innovative healthcare technology that connects clinicians, patients, payers, and partners in differentiated ways. Our electronic health records, revenue cycle management, and patient engagement tools allow anytime, anywhere access, driving better financial outcomes for our customers and enabling our provider customers to deliver better quality care. In everything we do, we’re inspired by our vision to create a thriving ecosystem that delivers accessible, high-quality, and sustainable healthcare for all. About DrFirst Since 2000, DrFirst has pioneered healthcare technology solutions and consulting services that securely connect people at touchpoints of care to improve patient outcomes. We create unconventional solutions that solve care collaboration, medication management, price transparency, and adherence challenges faced in healthcare. We unite the Healthiverse—the interconnected healthcare universe—by providing our clients with real-time access to the information they need, exactly when and how they need it, so patients get the best care possible. DrFirst solutions are used by nearly 325,000 healthcare professionals, including 220,000 prescribers, 70,000 pharmacies, 290 HIS/EHRs, and 1,500 hospitals in the U.S. and Canada.

Read More